585 related articles for article (PubMed ID: 7682759)
1. Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer.
Siitonen SM; Kallioniemi OP; Isola JJ
Am J Pathol; 1993 Apr; 142(4):1081-9. PubMed ID: 7682759
[TBL] [Abstract][Full Text] [Related]
2. Proliferative activity is a significant prognostic factor in male breast carcinoma.
Pich A; Margaria E; Chiusa L
Am J Pathol; 1994 Aug; 145(2):481-9. PubMed ID: 7519830
[TBL] [Abstract][Full Text] [Related]
3. Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma.
Visakorpi T
J Pathol; 1992 Sep; 168(1):7-13. PubMed ID: 1360498
[TBL] [Abstract][Full Text] [Related]
4. Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.
Clark GM; Allred DC; Hilsenbeck SG; Chamness GC; Osborne CK; Jones D; Lee WH
Cancer Res; 1997 Dec; 57(24):5505-8. PubMed ID: 9407959
[TBL] [Abstract][Full Text] [Related]
5. Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer.
Aaltomaa S; Lipponen P; Syrjänen K
Anticancer Res; 1993; 13(2):533-8. PubMed ID: 8100128
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1.
Kreipe H; Alm P; Olsson H; Hauberg M; Fischer L; Parwaresch R
Am J Pathol; 1993 Feb; 142(2):651-7. PubMed ID: 8094598
[TBL] [Abstract][Full Text] [Related]
7. PC-10 antibody to proliferating cell nuclear antigen (PCNA) is not related to prognosis in human breast carcinoma.
Gasparini G; Meli S; Pozza F; Cazzavillan S; Bevilacqua P
Growth Regul; 1992 Dec; 2(4):145-50. PubMed ID: 1363282
[TBL] [Abstract][Full Text] [Related]
8. Proliferating cell nuclear antigen (PCNA), immunostaining and flow cytometric DNA analysis of renal cell carcinoma.
Tanioka F; Hiroi M; Yamane T; Hara H
Zentralbl Pathol; 1993 Aug; 139(3):185-93. PubMed ID: 8105885
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of cell proliferation in breast cancer as determined by proliferating cell nuclear antigen (PCNA) immunostaining.
Aaltomaa S; Lipponen P; Syrjänen K
Anticancer Res; 1992; 12(4):1281-6. PubMed ID: 1380227
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness.
Gasparini G; Pozza F; Meli S; Reitano M; Santini G; Bevilacqua P
Anticancer Res; 1991; 11(6):2015-21. PubMed ID: 1776834
[TBL] [Abstract][Full Text] [Related]
11. The proliferative fraction in lymph nodes: a comparison of proliferating cell nuclear antigen morphometry to flow cytometry.
Krauss JS; Pantazis CG; Chandler FW
Ann Clin Lab Sci; 1992; 22(3):189-96. PubMed ID: 1354428
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinomas: comparison with clinical and pathologic variables.
Frierson HF
Mod Pathol; 1993 May; 6(3):290-4. PubMed ID: 8102204
[TBL] [Abstract][Full Text] [Related]
13. Optimization of immunohistochemical staining of proliferating cells in paraffin sections of breast carcinoma using antibodies to proliferating cell nuclear antigen and the Ki-67 antigen.
Yu CC; Dublin EA; Camplejohn RS; Levison DA
Anal Cell Pathol; 1995 Jul; 9(1):45-52. PubMed ID: 7577754
[TBL] [Abstract][Full Text] [Related]
14. Lack of correlation between flow cytometric and immunohistologic proliferation measurements of tumors.
Linden MD; el-Naggar AK; Nathanson SD; Jacobson G; Zarbo RJ
Mod Pathol; 1996 Jun; 9(6):682-9. PubMed ID: 8782208
[TBL] [Abstract][Full Text] [Related]
15. Comparison of proliferation activity in breast carcinoma by flow cytometry analysis of S-phase and quantitative analysis of MIB-1.
Masood S; Bui MM; Lu L
Ann Clin Lab Sci; 1998; 28(6):315-23. PubMed ID: 9846198
[TBL] [Abstract][Full Text] [Related]
16. KiS1--a novel monoclonal antibody which recognizes proliferating cells: evaluation of its relationship to prognosis in mammary carcinoma.
Sampson SA; Kreipe H; Gillett CE; Smith P; Chaudary MA; Khan A; Wicks K; Parwaresch R; Barnes DM
J Pathol; 1992 Oct; 168(2):179-85. PubMed ID: 1460535
[TBL] [Abstract][Full Text] [Related]
17. Proliferating cell nuclear antigen immunostaining in breast cancer and its relation to prognosis.
Narita T; Funahashi H; Satoh Y; Takagi H
Jpn J Clin Oncol; 1993 Feb; 23(1):20-5. PubMed ID: 8096256
[TBL] [Abstract][Full Text] [Related]
18. Comparative predictive value of three prognostic markers--S-phase fraction, PCNA and Mitotic count on axillary lymph node metastasis in carcinoma breast.
Pervez S; Khan MN; Nasir MI
J Ayub Med Coll Abbottabad; 2007; 19(1):3-5. PubMed ID: 17867469
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein.
Domagala W; Markiewski M; Harezga B; Dukowicz A; Osborn M
Clin Cancer Res; 1996 Jan; 2(1):147-54. PubMed ID: 9816101
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms.
Goldblum JR; Shannon R; Kaldjian EP; Thiny M; Davenport R; Thompson N; Lloyd RV
Mod Pathol; 1993 Nov; 6(6):663-8. PubMed ID: 7508113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
